Total Funding
65
37
Total FundingSeries C raised
Growth Score
-2 pts
Heat Score
-7 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
83148
Gmax Biopharm develops GPCR antibody therapeutics for unmet medical needs in cardiovascular diseases, metabolic disorders, and cancer.
- Dexter Fong: Chief Financial Officer
- Shuqian Jing: Founder, Chairman & CEO
About the Company
Gmax Biopharm develops GPCR antibody therapeutics for unmet medical needs in cardiovascular diseases, metabolic disorders, and cancer. Gmax Biopharm develops a proprietary platform with a systemic approach to GPCR MAb generation, screening, and development. Gmax Biopharm enables antibody screening, humanization, and engineering to produce antibody
candidates with high drugability and developability.
